CAMBRIDGE, Mass., & MONTREAL--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Paladin Labs Inc., an operating company of Endo International plc (NASDAQ: ENDP) (TSX: ENL), today announced that ARIAD has granted Paladin exclusive rights to distribute Iclusig™ (as ponatinib hydrochloride) in Canada for its newly approved indications. Paladin is focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.
Help employers find you! Check out all the jobs and post your resume.
